Business Description
Celyad Oncology SA
ISIN : BE0974260896
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
CYAD.BelgiumCLYYF.USA1C0.Germany0QFK.UK IPO Date
2014-01-06Description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.06 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | 0.76 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -113.45 | |||||
Beneish M-Score | 10.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 69.5 | |||||
3-Year FCF Growth Rate | 50.6 | |||||
3-Year Book Growth Rate | -34.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.13 | |||||
9-Day RSI | 3.94 | |||||
14-Day RSI | 14.76 | |||||
3-1 Month Momentum % | -28.57 | |||||
6-1 Month Momentum % | 38.89 | |||||
12-1 Month Momentum % | -50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.92 | |||||
Cash Ratio | 0.94 | |||||
Days Inventory | 15330 | |||||
Days Sales Outstanding | 932.78 | |||||
Days Payable | 40530.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.6 | |||||
Shareholder Yield % | -7.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.91 | |||||
Operating Margin % | -6400 | |||||
Net Margin % | 3952.38 | |||||
EBITDA Margin % | 5228.57 | |||||
FCF Margin % | -33425 | |||||
OCF Margin % | -33425 | |||||
ROE % | Neg. Equity | |||||
ROA % | 12.5 | |||||
ROIC % | -30.61 | |||||
3-Year ROIIC % | -300.39 | |||||
ROC (Joel Greenblatt) % | 59.61 | |||||
ROCE % | 23.24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.44 | |||||
PB Ratio | 4.81 | |||||
Price-to-Tangible-Book | 5 | |||||
EV-to-EBIT | 11.11 | |||||
EV-to-EBITDA | 9.04 | |||||
EV-to-Revenue | 472.86 | |||||
EV-to-FCF | -1.44 | |||||
Price-to-GF-Value | 1.67 | |||||
| Price-to-Net-Current-Asset-Value | 6.25 | |||||
Earnings Yield (Greenblatt) % | 9 | |||||
FCF Yield % | -59.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CLYYF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celyad Oncology SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.024 | ||
| EPS (TTM) ($) | 0.022 | ||
| Beta | -2.6572 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.59 | ||
| Volatility % | 155.39 | ||
| 14-Day RSI | 14.76 | ||
| 14-Day ATR ($) | 0.000346 | ||
| 20-Day SMA ($) | 0.25 | ||
| 12-1 Month Momentum % | -50 | ||
| 52-Week Range ($) | 0.15 - 0.53 | ||
| Shares Outstanding (Mil) | 44.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celyad Oncology SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celyad Oncology SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2024 | 2024-08-02 | 0.25 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-02 | 0.25 (+0.00%) |
Show
Entries
Celyad Oncology SA Frequently Asked Questions
What is Celyad Oncology SA(CLYYF)'s stock price today?
The current price of CLYYF is $0.25. The 52 week high of CLYYF is $0.53 and 52 week low is $0.15.
When is next earnings date of Celyad Oncology SA(CLYYF)?
The next earnings date of Celyad Oncology SA(CLYYF) is .
Does Celyad Oncology SA(CLYYF) pay dividends? If so, how much?
Celyad Oncology SA(CLYYF) does not pay dividend.
Guru Commentaries on OTCPK:CLYYF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Celyad Oncology SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers